Last reviewed · How we verify
NCT06195150: ITHORinVHL
Overtaking Intra and Inter Tumoral Heterogeneity In Von Hippel-Lindau Related Renal Cancer
trial testing Blood collection in Clear Cell Renal Cell Carcinoma in 3 participants. Currently enrolling.
31 October 2025
Quick facts
| Lead sponsor | IRCCS San Raffaele |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 3 |
| Start date | 8 November 2023 |
| Primary completion | 31 October 2025 |
| Estimated completion | 31 October 2025 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- Blood collection — full drug profile →
Conditions studied
- Clear Cell Renal Cell Carcinoma — all drugs for Clear Cell Renal Cell Carcinoma →
- VHL Syndrome — all drugs for VHL Syndrome →
Sponsor
IRCCS San Raffaele — full company profile →
Who can join
Adults 18 to 99, any sex, with Clear Cell Renal Cell Carcinoma or VHL Syndrome. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this study is to comprehensively map intra and inter tumor heterogeneity of ccRCC in VHL patients through the use of imaging, molecular biology and genomics techniques.
Publications & conference data
5 peer-reviewed publications reference this trial (live from Europe PMC):
-
Tumour organoids and assembloids: Patient-derived cancer avatars for immunotherapy.
Mei J, Liu X, Tian HX, Chen Y, et al · · 2024 · cited 25× · PMID 38664597 · DOI 10.1002/ctm2.1656 -
Single-cell RNA sequencing: enhancing the predictive accuracy of tumor immunotherapy efficacy.
Zhou W, Huang Z, Wu Z, Tang M, et al · · 2025 · cited 3× · PMID 40857744 · DOI 10.1042/ebc20253017 -
Single-cell sequencing technology in renal cancer: insights into tumor biology and clinical application.
Zhang H, Liu Y, Liu W, Lin A, et al · · 2025 · cited 1× · PMID 41035074 · DOI 10.1186/s40364-025-00811-0 -
Intra- and inter-tumoural heterogeneity in von Hippel-Lindau disease-related renal cancer: a multimodal data study protocol.
Rowe I, Colombo A, Corea F, Pisu F, et al · · 2025 · PMID 41241877 · DOI 10.1186/s41747-025-00648-0 -
Advances in precision oncology using patient-derived organoids and functional biomaterials.
Singh H, Mijakovic I, Singh P. · · 2025 · PMID 41098309 · DOI 10.3389/fcell.2025.1670328
Verify or expand the search:
- PubMed search for NCT06195150
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Blood collection
Trials testing the same drug.
- NCT07134491 — Peripheral and Intrarenal B Cell Study in Antibody Mediated Transplant Rejection : Phenotypic and Transcriptional Study, · recruiting
- NCT07075107 — Transcriptomic Analysis of Fibroblasts and Blood in Patients With Rare Diseases · NA · not yet recruiting
- NCT06510868 — Evaluating Myelodysplastic Syndrome Risks in NET Patients Planned for Peptide Radionuclide Therapy · recruiting
- NCT06521502 — The APS Phenotyping Study · recruiting
- NCT06373510 — Longitudinal Evaluation of Antibody Kinetics of Vaccinated Patients With Non-mandatory Vaccine Following Administration · NA · not yet recruiting
Other recruiting trials for Clear Cell Renal Cell Carcinoma
Currently open trials in the same condition.
- NCT06863311 — Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear C · Phase 2 · recruiting
- NCT07227415 — Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Antica · Phase 1, PHASE2 · recruiting
- NCT07187778 — Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal · Phase 2 · recruiting
- NCT07389629 — Iparomlimab and Tuvonralimab (QL1706) Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC · Phase 2 · recruiting
- NCT06805825 — A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Expres · Phase 1 · recruiting
Other IRCCS San Raffaele trials
Trials by the same sponsor.
- NCT07454759 — Acute Sarcopenia in Hospitalized Older Adults · not yet recruiting
- NCT07456462 — Making Antibody Treatments More Effective in Early Alzheimer's Disease Using 3Tesla Magnetica Resonance · NA · not yet recruiting
- NCT07066878 — This Protocol Focuses on the Factors That Influence Survival, the Development of Complications and the Quality of Life B · not yet recruiting
- NCT07526298 — Anticipating Irreversible Disability in Neuromyelitis Optica Spectrum Disorder: a Study to Assess Disease Activity in Ap · not yet recruiting
- NCT07426471 — Delafloxacin Plasma and Tissue Concentration in Patients With Skin, Soft Tissue, and Bone and Joint Infections. · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06195150 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by IRCCS San Raffaele
- Last refreshed: 1 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06195150.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing